Empirical Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.4M Buy
5,575
+2,154
+63% +$463K 0.32% 91
2026
Q1
$744K Sell
3,421
-6,844
-67% -$1.52M 0.2% 137
2025
Q4
$757K Sell
10,265
-107
-1% -$24.4K 0.21% 130
2025
Q3
$792K Buy
10,372
+6,986
+206% +$1.42M 0.22% 145
2025
Q2
$629K Sell
3,386
-40
-1% -$7.43K 0.19% 162
2025
Q1
$718K Sell
3,426
-222,837
-98% -$43.3M 0.24% 120
2024
Q4
$741K Buy
226,263
+192,734
+575% +$35.4M 0.25% 115
2024
Q3
$607K Sell
33,529
-397
-1% -$74.1K 0.22% 141
2024
Q2
$600K Buy
33,926
+27,131
+399% +$4.49M 0.23% 127
2024
Q1
$434K Buy
6,795
+4,264
+168% +$735K 0.21% 129
2023
Q4
$392K Buy
2,531
+120
+5% +$17.5K 0.32% 111
2023
Q3
$359K Buy
2,411
+54
+2% +$7.93K 0.31% 110
2023
Q2
$318K Sell
2,357
-1
-0% -$147 0.28% 110
2023
Q1
$376K Sell
2,358
-337
-13% -$51.5K 0.36% 98
2022
Q4
$381K Buy
2,695
+334
+14% +$51.2K 0.4% 98
2022
Q3
$317K Sell
2,361
-3
-0.1% -$430 0.35% 107
2022
Q2
$362K Buy
2,364
+19
+0.8% +$2.9K 0.38% 100
2022
Q1
$380K Buy
+2,345
New +$341K 0.36% 97

Other funds holding ABBV

Empirical Asset Management's ABBV Position: Q2 2026 in Review

Empirical Asset Management increased its AbbVie (ABBV) stake by 63% in Q2 2026, buying an estimated $463K and bringing the position to 5,575 shares worth $1.4M. The position accounts for 0.32% of the portfolio, ranked #91.

Empirical Asset Management first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Empirical Asset Management held 5,575 shares of AbbVie worth $1.4M as of Q2 2026.
  • Empirical Asset Management bought 2,154 AbbVie shares in Q2 2026, an estimated $463K.
  • AbbVie made up 0.32% of Empirical Asset Management's portfolio in Q2 2026, its #91 holding.
  • Empirical Asset Management first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Empirical Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.